Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

The fact they have purposefully chosen to do an early data release on an open label trial is a huge indication the data is positive.

Earlier I described why: releasing early means you are not benefiting from achieving full trial "power". This refers to the ability to detect a meaningful difference if one exists. If you show early results, with fewer patients, you are less likely to show positive signal than if you wait... because the more patients, the easier it becomes to find a positive signal (statistically speaking) TRANSLATION: there is only one reason companies do this... the data is overwhelmingly positive and they want to show us ASAP.